This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zambon, A. Articles by Brunzell, J. D. Search for Related Content PubMed PubMed Citation Articles by Zambon, A. Articles by Brunzell, J. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB LOVASTATIN NICOTINIC ACID Related Collections Genetics of cardiovascular disease Lipid and lipoprotein metabolism

(Circulation. 2001;103:792.)
© 2001 American Heart Association, Inc.

Clinical Investigation and Reports

Common Hepatic Lipase Gene Promoter Variant Determines Clinical Response to Intensive Lipid-Lowering Treatment

Alberto Zambon, MD, PhD; Samir S. Deeb, PhD; B. Greg Brown, MD, PhD; John E. Hokanson, PhD; John D. Brunzell, MD

From the Department of Medicine, University of Washington, Seattle.

Correspondence to John D. Brunzell, MD, University of Washington, Department of Medicine, 1959 NE Pacific St, Box 356426, Seattle, WA 98195-6426. E-mail brunzell{at}u.washington.edu

Background—The common -514 CT polymorphism in the promoter region of the hepatic lipase (HL) gene affects HL activity. The C allele is associated with higher HL activity, more dense and atherogenic LDL, and lower HDL₂ cholesterol. Intensive lipid-lowering therapy lowers HL activity, increases LDL and HDL buoyancy, and promotes coronary artery disease (CAD) regression. We tested the hypothesis that subjects with the CC genotype and a more atherogenic lipid profile experience the greatest CAD regression from these favorable effects.

Methods and Results—Forty-nine middle-aged men with dyslipidemia and established CAD who were undergoing intensive lipid-lowering therapy were studied. Change in coronary stenosis was assessed by quantitative angiography, HL polymorphism by polymerase chain reaction amplification, HL activity by ¹⁴C-labeled substrate, and LDL buoyancy by density-gradient ultracentrifugation. The response to lipid-lowering therapy was significantly different among subjects with different HL promoter genotypes. Subjects with the CC genotype had the greatest decrease in HL activity (P<0.005 versus TC and TT by ANOVA) and the greatest improvement in LDL density (P<0.005) and HDL₂-C (P<0.05) with therapy. These subjects had the greatest angiographic improvement, with 96% of them experiencing CAD regression, compared with 60% of TC and none of the TT patients (P<0.001).

Conclusions—In middle-aged men with established CAD and dyslipidemia, the HL gene -514 CT polymorphism significantly predicts changes in coronary stenosis with lipid-lowering treatment that appear to involve an HL-associated effect on LDL metabolism. This study identifies a gene polymorphism that strongly influences the lipid and clinical response to lipid-lowering drugs.

Key Words: coronary artery disease • liver • genes • lipoproteins • pharmacogenetics

This article has been cited by other articles:

				Y.-M. Fan, P. Dastidar, H. Jokela, R. Punnonen, and T. Lehtimaki Hepatic Lipase C-480T Genotype-Dependent Benefit from Long-Term Hormone Replacement Therapy for Atherosclerosis Progression in Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3786 - 3792. [Abstract] [Full Text] [PDF]

				G. F. Lewis, S. Murdoch, K. Uffelman, M. Naples, L. Szeto, A. Albers, K. Adeli, and J. D. Brunzell Hepatic Lipase mRNA, Protein, and Plasma Enzyme Activity Is Increased in the Insulin-Resistant, Fructose-Fed Syrian Golden Hamster and Is Partially Normalized by the Insulin Sensitizer Rosiglitazone Diabetes, November 1, 2004; 53(11): 2893 - 2900. [Abstract] [Full Text] [PDF]

				H. Gonzalez-Navarro, Z. Nong, M. J. A. Amar, R. D. Shamburek, J. Najib-Fruchart, B. J. Paigen, H. B. Brewer Jr., and S. Santamarina-Fojo The Ligand-binding Function of Hepatic Lipase Modulates the Development of Atherosclerosis in Transgenic Mice J. Biol. Chem., October 29, 2004; 279(44): 45312 - 45321. [Abstract] [Full Text] [PDF]

				S. Santamarina-Fojo, H. Gonzalez-Navarro, L. Freeman, E. Wagner, and Z. Nong Hepatic Lipase, Lipoprotein Metabolism, and Atherogenesis Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1750 - 1754. [Abstract] [Full Text] [PDF]

				A. Isaacs, F. A. Sayed-Tabatabaei, O. T. Njajou, J. C. M. Witteman, and C. M. van Duijn The -514 C->T Hepatic Lipase Promoter Region Polymorphism and Plasma Lipids: A Meta-Analysis J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3858 - 3863. [Abstract] [Full Text] [PDF]

				Y. Bosse, L. Perusse, and M.-C. Vohl Genetics of LDL particle heterogeneity: from genetic epidemiology to DNA-based variations J. Lipid Res., June 1, 2004; 45(6): 1008 - 1026. [Abstract] [Full Text] [PDF]

				R. M. Krauss Lipids and Lipoproteins in Patients With Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1496 - 1504. [Abstract] [Full Text] [PDF]

				A. M. Gotto Jr and E. A. Brinton Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update J. Am. Coll. Cardiol., March 3, 2004; 43(5): 717 - 724. [Abstract] [Full Text] [PDF]

				Y M Fan, J T Salonen, T A Koivu, T-P Tuomainen, K Nyyssonen, T A Lakka, R Salonen, K Seppanen, S T Nikkari, E Tahvanainen, et al. Hepatic lipase C-480T polymorphism modifies the effect of HDL cholesterol on the risk of acute myocardial infarction in men: a prospective population based study J. Med. Genet., March 1, 2004; 41(3): e28 - 28. [Full Text] [PDF]

				M. A. Austin, K. L. Edwards, S. A. Monks, K. M. Koprowicz, J. D. Brunzell, A. G. Motulsky, M. C. Mahaney, and J. E. Hixson Genome-wide scan for quantitative trait loci influencing LDL size and plasma triglyceride in familial hypertriglyceridemia J. Lipid Res., November 1, 2003; 44(11): 2161 - 2168. [Abstract] [Full Text] [PDF]

				F. M. Sacks and H. Campos Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4525 - 4532. [Full Text] [PDF]

				S. S. Deeb, A. Zambon, M. C. Carr, A. F. Ayyobi, and J. D. Brunzell Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet J. Lipid Res., July 1, 2003; 44(7): 1279 - 1286. [Abstract] [Full Text] [PDF]

				R. V. Andersen, H. H. Wittrup, A. Tybjaerg-Hansen, R. Steffensen, P. Schnohr, and B.o. G. Nordestgaard Hepatic lipase mutations,elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: The Copenhagen City Heart Study J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1972 - 1982. [Abstract] [Full Text] [PDF]

				J. L. Anderson and J. F. Carlquist Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: Do they add up yet? J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1990 - 1993. [Full Text] [PDF]

				J. L. Anderson, J. F. Carlquist, B. D. Home, and J. B. Muhlestein Cardiovascular Pharmacogenomics: Current Status, Future Prospects Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 71 - 83. [Abstract] [PDF]

				I. I.L. Berk-Planken, N. Hoogerbrugge, R. P. Stolk, A. H. Bootsma, and H. Jansen Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes: Effect of sex and the LIPC promoter variant Diabetes Care, February 1, 2003; 26(2): 427 - 432. [Abstract] [Full Text] [PDF]

				Y. Somekawa, H. Umeki, K. Kobayashi, S. Tomura, T. Aso, and H. Hamaguchi Effects of Hormone Replacement Therapy and Hepatic Lipase Polymorphism on Serum Lipid Profiles in Postmenopausal Japanese Women J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4766 - 4770. [Abstract] [Full Text] [PDF]

				B. G. Brown, M. C. Cheung, A. C. Lee, X.-Q. Zhao, and A. Chait Antioxidant Vitamins and Lipid Therapy: End of a Long Romance? Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1535 - 1546. [Abstract] [Full Text] [PDF]

				E. Faggin, A. Zambon, M. Puato, S. S. Deeb, S. Bertocco, S. Sartore, G. Crepaldi, A. C. Pessina, and P. Pauletto Association between the -514 c->t polymorphism of the hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1059 - 1066. [Abstract] [Full Text] [PDF]

				B. Perret, L. Mabile, L. Martinez, F. Terce, R. Barbaras, and X. Collet Hepatic lipase: structure/function relationship, synthesis, and regulation J. Lipid Res., August 1, 2002; 43(8): 1163 - 1169. [Abstract] [Full Text] [PDF]

				H. Knoblauch, A. Bauerfeind, C. Krahenbuhl, A. Daury, K. Rohde, S. Bejanin, L. Essioux, H. Schuster, F. C. Luft, and J. Georg Reich Common haplotypes in five genes influence genetic variance of LDL and HDL cholesterol in the general population Hum. Mol. Genet., June 1, 2002; 11(12): 1477 - 1485. [Abstract] [Full Text] [PDF]

				J. E. Hokanson, S. Cheng, J. K. Snell-Bergeon, B. A. Fijal, M. A. Grow, C. Hung, H. A. Erlich, J. Ehrlich, R. H. Eckel, and M. Rewers A Common Promoter Polymorphism in the Hepatic Lipase Gene (LIPC-480C>T) Is Associated With an Increase in Coronary Calcification in Type 1 Diabetes Diabetes, April 1, 2002; 51(4): 1208 - 1213. [Abstract] [Full Text] [PDF]

				K. A. Dugi, K. Brandauer, N. Schmidt, B. Nau, J. G. Schneider, S. Mentz, T. Keiper, J. R. Schaefer, C. Meissner, H. Kather, et al. Low Hepatic Lipase Activity Is a Novel Risk Factor for Coronary Artery Disease Circulation, December 18, 2001; 104(25): 3057 - 3062. [Abstract] [Full Text] [PDF]